Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 1.00 |
| ▸ | PPARD | Q03181 | 6/20 | 1.00 |
| ▸ | PPARA | Q07869 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | F7 | P08709 | 5/20 | 1.00 |
| ▸ | F3 | P13726 | 5/20 | 1.00 |
| ▸ | FABP4 | P15090 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | FFAR1 | O14842 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | DUSP3 | P51452 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18274948 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL18274979 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| Linoleic Acid SCHEMBL20856202 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL22498259 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL22498256 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| Arachidic Acid SCHEMBL20528087 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| Linoleic Acid SCHEMBL25294178 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL22498258 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| Dihomo-Gamma-Linolenic Acid SCHEMBL20656585 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL21411004 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023213310-A9 | CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF | 太阳雨林(北京)生物医药有限公司 | 2025-02-20 | — | — | WO | disclosed |
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | JINA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| CN-115607677-A | Compound for preventing, preventing or treating microbial infection and preparation and application thereof | 太阳雨林(北京)生物医药有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-114569726-B | Compound for preventing, preventing or treating microbial infection and preparation method and application thereof | 太阳雨林(北京)生物医药有限公司 | 2022-10-28 | — | — | CN | disclosed |
| US-20210177752-A1 | ENDOXIFEN METHODS AND COMPOSITIONS FOR INHIBITION OF PROTEIN KINASE C | JINA PHARMACEUTICALS, INC. | 2021-06-17 | — | — | US | disclosed |
| US-20200345849-A1 | Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof | JINA PHARMACEUTICALS, INC. (US) | 2020-11-05 | — | — | US | disclosed |
| EP-2344198-B1 | LIPID BASED PHARMACEUTICAL PREPARATIONS FOR TOPICAL APPLICATION | JINA PHARMACEUTICALS INC (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20200155575-A1 | PHARMACEUTICAL COMPOSITION AND METHODS | LIPOCINE INC. (US) | 2020-05-21 | — | — | US | disclosed |
| US-20190269700-A1 | PHARMACEUTICAL COMPOSITION AND METHODS | LIPOCINE INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-10376479-B2 | Endoxifen compositions and methods | JINA PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20050277611-A1 | Cationic cardiolipin analoges and its use thereof | NEOPHARM, INC. (US) | 2005-12-15 | — | — | US | disclosed |
| US-20050266068-A1 | Cardiolipin molecules and methods of synthesis | NEOPHARM, INC. (US) | 2005-12-01 | — | — | US | disclosed |
| US-20050181037-A1 | Cardiolipin compositions their methods of preparation and use | NEOPHARM, INC. (US) | 2005-08-18 | — | — | US | disclosed |
| EP-1558562-A1 | CATIONIC CARDIOLIPIN ANALOGS AND USE THEREOF | Neopharm, Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| EP-1556392-A1 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | Neopharm, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1513853-A2 | CARDIOLIPIN COMPOSITIONS, METHODS OF PREPARATION AND USE | Neopharm, Inc. (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004039817-A9 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | NEOPHARM INC (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004039817-A1 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | NEOPHARM, INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004035523-A1 | CATIONIC CARDIOLIPIN ANALOGS AND USE THEREOF | NEOPHARM, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003099830-A2 | CARDIOLIPIN COMPOSITIONS, METHODS OF PREPARATION AND USE | NEOPHARM, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10376479-B2 | Endoxifen compositions and methods | CYP46A1, PLA2G2F, VDR | PPARG 258/4885PPARD 513/4885PPARA 591/4885 |
| US-20050277611-A1 | Cationic cardiolipin analoges and its use thereof | LCLAT1, CETP, LIPA | PPARG 1493/4885PPARD 1831/4885PPARA 1028/4885 |
| US-20210177752-A1 | ENDOXIFEN METHODS AND COMPOSITIONS FOR INHIBITION OF PROTEIN KINASE C | EEF2K, LITAF, RAPGEF3 | PPARG 846/4885PPARD 2319/4885PPARA 1620/4885 |
| US-20050266068-A1 | Cardiolipin molecules and methods of synthesis | PHOSPHO1, MGLL, LIPA | PPARG 453/4885PPARD 606/4885PPARA 333/4885 |
| US-20050181037-A1 | Cardiolipin compositions their methods of preparation and use | LIPA, LCLAT1, PHOSPHO1 | PPARG 386/4885PPARD 435/4885PPARA 246/4885 |
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | EEF2K, LITAF, RAPGEF3 | PPARG 846/4885PPARD 2319/4885PPARA 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.